CU20180108A7 - Composiciones de hierro ferroso en una matriz proteica para aumentar la ingesta de hierro en mamíferos y su procedimiento de preparación - Google Patents
Composiciones de hierro ferroso en una matriz proteica para aumentar la ingesta de hierro en mamíferos y su procedimiento de preparaciónInfo
- Publication number
- CU20180108A7 CU20180108A7 CU2018000108A CU20180108A CU20180108A7 CU 20180108 A7 CU20180108 A7 CU 20180108A7 CU 2018000108 A CU2018000108 A CU 2018000108A CU 20180108 A CU20180108 A CU 20180108A CU 20180108 A7 CU20180108 A7 CU 20180108A7
- Authority
- CU
- Cuba
- Prior art keywords
- iron
- percent
- compositions
- liquid
- protein matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
<p>La presente invención se refiere a composiciones orales que comprenden básicamente hierro ferroso (2,5 - 50 porciento p/p), un agente de tamponamiento (5 - 50 porciento p/p) y un vehículo a base de proteína desnaturalizada (5 - 80 porciento p/p) que son capaces de elevar el hierro sérico en un individuo. Dichas composiciones liberan al menos 80 porciento de la carga total de hierro ferroso en el transcurso de 30 min en un fluido gástrico simulado. Para ello, se han preparado microesferas secadas por pulverización que comprenden hierro atrapado dentro de una matriz proteica y hierro no unido en una composición tamponada que proporciona un efecto gastroprotector que preserva el hierro en la forma más disponible de Fe2+ y mejora la biodisponibilidad del hierro en humanos. Se refiere además a un procedimiento para la preparación de dichas composiciones que comprende la formación de hidrogeles a partir de un líquido que contiene hierro, proteína desnaturalizada y opcionalmente un agente tampón, el cizallamiento para formar partículas de gel dentro del líquido y someter este líquido a secado para obtener partículas secas.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16160539 | 2016-03-15 | ||
| PCT/EP2017/056134 WO2017158030A1 (en) | 2016-03-15 | 2017-03-15 | Compositions and methods for increasing iron intake in a mammal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20180108A7 true CU20180108A7 (es) | 2019-09-04 |
Family
ID=55640537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2018000108A CU20180108A7 (es) | 2016-03-15 | 2017-03-15 | Composiciones de hierro ferroso en una matriz proteica para aumentar la ingesta de hierro en mamíferos y su procedimiento de preparación |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US11224615B2 (es) |
| EP (1) | EP3429560B1 (es) |
| JP (1) | JP7193145B2 (es) |
| KR (1) | KR102403292B1 (es) |
| CN (1) | CN109069430B (es) |
| AU (1) | AU2017232266B2 (es) |
| BR (1) | BR112018068571A2 (es) |
| CA (1) | CA3017556C (es) |
| CL (1) | CL2018002632A1 (es) |
| CO (1) | CO2018010940A2 (es) |
| CR (1) | CR20180488A (es) |
| CU (1) | CU20180108A7 (es) |
| EA (1) | EA201892065A1 (es) |
| EC (1) | ECSP18077068A (es) |
| ES (1) | ES3008084T3 (es) |
| GE (2) | GEAP202214903A (es) |
| HR (1) | HRP20250187T1 (es) |
| HU (1) | HUE070063T2 (es) |
| IL (1) | IL261735B (es) |
| MA (1) | MA43703A (es) |
| MX (1) | MX2018011227A (es) |
| MY (1) | MY196575A (es) |
| NI (1) | NI201800089A (es) |
| NZ (1) | NZ747227A (es) |
| PE (1) | PE20181955A1 (es) |
| PH (1) | PH12018501994A1 (es) |
| PL (1) | PL3429560T3 (es) |
| SA (1) | SA518400019B1 (es) |
| SG (1) | SG11201807985XA (es) |
| UA (1) | UA125211C2 (es) |
| WO (1) | WO2017158030A1 (es) |
| ZA (1) | ZA201806814B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114027507B (zh) * | 2021-11-18 | 2023-02-28 | 中国农业大学 | 一种口服凝胶铁补充剂及其制备方法 |
| WO2024145451A2 (en) * | 2022-12-29 | 2024-07-04 | Memorial Sloan-Kettering Cancer Center | Methods for restoring regenerative potential of aged lung alveoli and aged adult stem cell compartments |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US505986A (en) | 1893-10-03 | Pio marfori | ||
| US4167564A (en) | 1974-09-23 | 1979-09-11 | Albion Laboratories, Inc. | Biological assimilation of metals |
| US4067994A (en) | 1976-03-26 | 1978-01-10 | Zinpro Corporation | Iron methionine complex salts |
| US4216144A (en) * | 1977-10-20 | 1980-08-05 | Ashmead H H | Soluble iron proteinates |
| IT1150213B (it) | 1982-03-02 | 1986-12-10 | Italfarmaco Spa | Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche |
| IT1186787B (it) | 1985-11-06 | 1987-12-16 | Mediolanum Farmaceutici Srl | Ferro-derivati della globina e dell'acetilglobina dotati di elevata biodisponibilita',processo di preparazione e composizioni farmaceutiche |
| US5418010A (en) | 1990-10-05 | 1995-05-23 | Griffith Laboratories Worldwide, Inc. | Microencapsulation process |
| JP3404294B2 (ja) | 1998-08-11 | 2003-05-06 | 雪印乳業株式会社 | 鉄−ホエー蛋白質加水分解物複合体 |
| US6521247B1 (en) | 1999-08-13 | 2003-02-18 | Warner Chilcott Laboratories Ireland Limited | Dual iron containing nutritional supplement |
| EP2274987A3 (en) * | 2003-10-30 | 2011-03-30 | Arla Foods Amba | Stabilisers useful in low fat spread production |
| CN1557481A (zh) | 2004-02-04 | 2004-12-29 | 高春平 | 防治缺铁性贫血的天然营养剂 |
| US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| US7585527B2 (en) | 2005-09-19 | 2009-09-08 | Bala Venkataraman | Composition and method for treating iron deficiency anemia |
| WO2008022932A2 (en) * | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
| CN101143011B (zh) | 2007-10-09 | 2011-06-22 | 浙江大学 | 提高食物中铁素生物有效性的方法 |
| US20090124572A1 (en) | 2007-11-09 | 2009-05-14 | Deanna Jean Nelson | Iron-containing nutritional supplement |
| CN101928742B (zh) | 2009-06-23 | 2013-02-27 | 光明乳业股份有限公司 | 一种具有抗氧化性活性的乳清蛋白活性肽及其制备方法 |
| WO2012097155A1 (en) | 2011-01-14 | 2012-07-19 | Chiasma Inc. | Improved pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof |
| MY163079A (en) | 2011-07-15 | 2017-08-15 | Nestec Sa | Food-grade encapsulate and process for the production thereof |
| MX380927B (es) | 2011-09-22 | 2025-03-12 | Amip | Promotor de absorcion gi superior amortiguado. |
| WO2014148886A1 (en) | 2013-03-22 | 2014-09-25 | N.V. Nutricia | Fermented nutrition high in lactose with increased iron bioavailability |
| GB201416293D0 (en) * | 2014-09-15 | 2014-10-29 | Solvotrin Therapeutics Ltd | Methods and preparations |
| EP2995205A1 (en) * | 2014-09-15 | 2016-03-16 | Anabio Technologies Limited | Compositions and methods for the maintenance of adequate iron intake in a mammal |
-
2017
- 2017-03-15 PL PL17710019.5T patent/PL3429560T3/pl unknown
- 2017-03-15 JP JP2019500009A patent/JP7193145B2/ja active Active
- 2017-03-15 KR KR1020187029764A patent/KR102403292B1/ko active Active
- 2017-03-15 BR BR112018068571-2A patent/BR112018068571A2/pt not_active Application Discontinuation
- 2017-03-15 EP EP17710019.5A patent/EP3429560B1/en active Active
- 2017-03-15 GE GEAP202214903A patent/GEAP202214903A/en unknown
- 2017-03-15 MA MA043703A patent/MA43703A/fr unknown
- 2017-03-15 MY MYPI2018703264A patent/MY196575A/en unknown
- 2017-03-15 CU CU2018000108A patent/CU20180108A7/es unknown
- 2017-03-15 IL IL261735A patent/IL261735B/en unknown
- 2017-03-15 UA UAA201810174A patent/UA125211C2/uk unknown
- 2017-03-15 MX MX2018011227A patent/MX2018011227A/es unknown
- 2017-03-15 ES ES17710019T patent/ES3008084T3/es active Active
- 2017-03-15 WO PCT/EP2017/056134 patent/WO2017158030A1/en not_active Ceased
- 2017-03-15 US US16/085,336 patent/US11224615B2/en active Active
- 2017-03-15 SG SG11201807985XA patent/SG11201807985XA/en unknown
- 2017-03-15 PE PE2018001822A patent/PE20181955A1/es unknown
- 2017-03-15 AU AU2017232266A patent/AU2017232266B2/en active Active
- 2017-03-15 CN CN201780024553.2A patent/CN109069430B/zh active Active
- 2017-03-15 NZ NZ747227A patent/NZ747227A/en unknown
- 2017-03-15 GE GEAP201714903A patent/GEP20227445B/en unknown
- 2017-03-15 CA CA3017556A patent/CA3017556C/en active Active
- 2017-03-15 HR HRP20250187TT patent/HRP20250187T1/hr unknown
- 2017-03-15 EA EA201892065A patent/EA201892065A1/ru unknown
- 2017-03-15 HU HUE17710019A patent/HUE070063T2/hu unknown
- 2017-03-15 CR CR20180488A patent/CR20180488A/es unknown
-
2018
- 2018-09-13 SA SA518400019A patent/SA518400019B1/ar unknown
- 2018-09-13 CL CL2018002632A patent/CL2018002632A1/es unknown
- 2018-09-14 PH PH12018501994A patent/PH12018501994A1/en unknown
- 2018-09-17 NI NI201800089A patent/NI201800089A/es unknown
- 2018-10-11 CO CONC2018/0010940A patent/CO2018010940A2/es unknown
- 2018-10-12 EC ECSENADI201877068A patent/ECSP18077068A/es unknown
- 2018-10-12 ZA ZA2018/06814A patent/ZA201806814B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002332A (es) | Células nk crioreservadas precargadas con una construcción de anticuerpo. | |
| BR112022011456A2 (pt) | Proteínas recombinantes de ligação a complexo de peptídeo-mhc e geração e uso das mesmas | |
| MX2024004337A (es) | Composicion farmaceutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t. | |
| EA201992377A1 (ru) | Стабильная композиция антитела | |
| WO2018085469A3 (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| CO2018011733A2 (es) | Composición farmacéutica | |
| BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
| EP4403570A3 (en) | Anti-il-33 antibodies and uses thereof | |
| CL2018000238A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| BR112012028326A2 (pt) | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos | |
| WO2014134561A3 (en) | Quantification of vaccine compositions | |
| CO6351750A2 (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5 | |
| PE20141173A1 (es) | Composiciones y metodos para el tratamiento en aplicaciones clinicas de amplio espectro, no diferenciadas o combinadas | |
| BR112017005200A2 (pt) | composição, formulação comestível, e, método para aumentar o ferro sérico em um mamífero com necessidade do mesmo. | |
| BR112013002831A2 (pt) | anticorpos direcionados contra a il-17 | |
| ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
| BR112015029224A2 (pt) | Anticorpo de alvo duplo tnf-alfa/cxcl10, transformante, método de produção de um anticorpo de alvo duplo tnf-alfa/cxcl10, composição farmacêutica e método de prevenção ou tratamento de uma doença imunológica | |
| IL292894A (en) | Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof | |
| BR112014024256A8 (pt) | Composição biorrelevante homogênea, meio biorrelevante aquoso, métodos de preparar um meio biorrelevante aquoso e uma composição homogênea, e, uso do meio biorrelevante aquoso | |
| CN110636857A8 (zh) | 人红富铁激素的抗体及其用途 | |
| PH12018501994A1 (en) | Compositions and method for increasing iron intake in a mammal | |
| AR073967A1 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen al mismo | |
| JOP20180082A1 (ar) | تركيبات وطرق لزيادة امتصاص الحديد في ثديي | |
| BR112014013369A2 (pt) | métodos e sistemas para redobramento de proteína | |
| ES2549690B1 (es) | Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz |